. 2014 Mar 26;2014:348959. doi: 10.1155/2014/348959

Table 1.

Lipids, inflammatory markers, and insulin sensitivity after treatment.

	Placebo		Probiotic		Omega-3		Probiotic + omega-3
	Pretreatment	Posttreatment	Pretreatment	Posttreatment	Pretreatment	Posttreatment	Pretreatment	Posttreatment
Fasting blood glucose (mg/dL)	89.30 ± 3.3	91.92 ± 3.18^∗a	88 ± 1.01	79.38 ± 1.05^∗b	87.60 ± 1.4	83.93 ± 1.23^∗c	86.70 ± 2.15	74.46 ± 1.188^∗cd
Cholesterol (mg/dL)	197.80 ± 13.92	197.91 ± 13.93^a	165.10 ± 5.76	156.06 ± 5.85^∗a	165.50 ± 9.73	161.06 ± 9.74^∗a	215.10 ± 7.86	204.46 ± 7.73^∗a
Triglyceride (mg/dL)	128 ± 2.26	128.85 ± 27.7^a	140.70 ± 17.6	133.13 ± 17.39^∗ab	105.90 ± 6.53	102.62 ± 6.44^∗a	150.00 ± 8.49	138.74 ± 8.35^∗b
LDL (mg/dL)	136.30 ± 14.19	136.67 ± 14.2^a	102.80 ± 4.91	94.50 ± 4.31^b	106.10 ± 10.1	99.87 ± 10.08^∗b	150.30 ± 8.41	134.58 ± 7.93^∗a
HDL (mg/dL)	35.90 ± 2.85	35.46 ± 2.85^a	29.60 ± 1.12	34.93 ± 1.08^∗a	38.20 ± 1.65	40.66 ± 1.62^∗b	34.80 ± 2.23	42.13 ± 1.89^∗b
VLDL (mg/dL)	25.60 ± 5.45	25.77 ± 5.54^a	32.60 ± 4.38	26.62 ± 3.47^a	21.10 ± 1.3	20.51 ± 1.28^∗a	30.00 ± 1.69	27.74 ± 1.67^∗a
Atherogenic factor	196.80 ± 13.92	196.91 ± 13.93^a	164.10 ± 5.76	155.75 ± 5.8^a	164.50 ± 9.73	160.06 ± 9.74^∗a	214.10 ± 7.86	203.46 ± 7.73^∗a
Insulin level (μU/mL)	17.90 ± 0.52	18.26 ± 0.43^a	18.40 ± 0.27	17.59 ± 0.28^∗b	18.50 ± 0.23	17.84 ± 0.22^∗a	18.00 ± 0.3	16.75 ± 0.25^∗b
Insulin resistance	3.90 ± 0.1	4.11 ± 0.12^∗a	4.00 ± 0.03	3.44 ± 0.04^∗b	4.00 ± 0.08	3.69 ± 0.07^∗c	3.80 ± 0.08	3.07 ± 0.04^∗d
CRP (mg/L)	5.30 ± 0.58	5.35 ± 0.58^∗a	5.60 ± 0.52	4.36 ± 0.49^∗a	5.60 ± 0.74	5.26 ± 0.72^∗a	6.20 ± 0.41	4.22 ± 0.41^∗a

Values are mean ± SEM.

*Superscript indicates a significant difference between baseline and after treatment.

*<0.05 significantly different from the pretreatment level.

^a,b,c,dSuperscript indicates significant <0.05 difference in relative changes versus baseline compared between supplemented and placebo group.